B&KHKSE:02396 -0.26%8 EBITDA Margin % is -13,768.28% as of Dec. 2025. GuruFocus rates HKSE:02396 with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 936 Biotechnology companies, B&K ranks worse than 94.34% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. B&K's EBITDA for the
three
months ended in Dec. 2025 was HK$-79.44 Mil. B&K's Revenue for the
three
months ended in Dec. 2025 was HK$0.58 Mil. Therefore, B&K's EBITDA margin for the quarter that ended in Dec. 2025 was -13,768.28%.
B&K (HKSE:02396) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
B&K EBITDA Margin % Related Terms
B&K EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for B&K's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
B&K EBITDA Margin % Chart
B&K Annual Data
Trend
Dec23
Dec24
Dec25
EBITDA Margin %
-15,834.30
-75,958.42
-38,027.04
B&K Quarterly Data
Dec23
Dec24
May25
Sep25
Dec25
EBITDA Margin %
0.00
-17,512.54
0.00
0.00
-13,768.28
HKSE:02396 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, B&K's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
B&K EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, B&K's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where B&K's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
B&K (HKSE:02396) has a EBITDA Margin % of -13,768.28% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on B&K and its competitors. According to the industry distribution chart, B&K ranks #883 out of 936 companies in the Biotechnology industry, placing it in the top 94.3%.
Is B&K's EBITDA Margin % too high?
B&K's current EBITDA Margin % is -13,768.28%. Based on the distribution chart, B&K ranks #883 out of 936 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, B&K has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does B&K's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, B&K ranks #883 out of 936 companies for EBITDA Margin %. This places B&K in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on B&K and its competitors. B&K's current EBITDA Margin % is -13,768.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is B&K stock overvalued right now?
B&K (HKSE:02396) has a current EBITDA Margin % of -13,768.28%. The current EBITDA Margin % is -13,768.28%. B&K's overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For B&K (HKSE:02396), the current EBITDA Margin % is -13,768.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
B&K Corp Ltd is a China-based biopharmaceutical company committed to developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities. The company prominently focuses on the discovery, development and commercialization of therapies for wound healing, currently PDGF drugs. Its pipeline consisted of ten candidates, seven of which are PDGF candidates, including two Core Products, namely Pro-101-1 for the treatment of thermal burns and Pro-101-2 for the treatment of DFUs, which are rhPDGF-BB drugs. The company operates in a single reportable segment: the research and development of biopharmaceutical products. Geographically, the company generates all its revenue from Chinese Mainland.
8GF Score
Get the complete analysis for HKSE:02396
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02396 has been successfully added to your 